Rate of Pathologic Complete Responses to Docetaxel, Cisplatin, and Fluorouracil Induction Chemotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Abstract

Objective: To report the rate of pathological complete response after induction chemotherapy with the docetaxel, cisplatin, and fluorouracil (TPF) combination.

Efficacy and safety of nanosomal docetaxel lipid suspension‑based chemotherapy in squamous cell carcinoma of the head and neck: A multicenter retrospective study

“…Wang et al ( 33 ) used nimotuzumab, an anti-EGFR humanized monoclonal IgG1 antibody, in induction chemotherapy with the TPF regimen for LA SCCHN (n=31). This resulted in an ORR of 87.1% ( 30 ), compared with the 100% (CR, 2 patients; PR, 6 patients; 8 out of 8 evaluated, NE=1 excluded) recorded in the present study. In a phase III study, TPF induction chemotherapy followed by cetuximab showed a response rate of 78% ( 36 ), while the same regimen was used in 3 patients in the present study with 2 patients achieving a PR (100%, 2 out of 2 evaluated, NE=1 excluded).…”

Nonoperative Management Following Complete Response in Rectal Cancer After Short-course Radiation Therapy and Consolidation Chemotherapy

“…chemotherapy are well established in a variety of tumors and can influence local tumor outcomes, beyond their role in treating micrometastatic disease. 39,40 Taken together, these results indicate that intensified neoadjuvant therapy, including intensified chemotherapy, may lead to higher rates of local-regional tumor eradication and thus more patients with rectal cancer would be candidates for organ preservation. NOM for patients who achieve CR is appealing for many reasons including potentially better general and bowel QOL and avoidance of rectal side effects associated with LAR and avoidance of permanent ostomy after APR.…”

“…Chemotherapy itself can produce significant local responses at sites of bulky primary disease, including achieving complete pathologic regression in rectal cancer without radiation 38. These local effects of full-dose chemotherapy are well established in a variety of tumors and can influence local tumor outcomes, beyond their role in treating micrometastatic disease 39,40. Taken together, these results indicate that intensified neoadjuvant therapy, including intensified chemotherapy, may lead to higher rates of local-regional tumor eradication and thus more patients with rectal cancer would be candidates for organ preservation.…”

Identification and characterization of Dicer1e, a Dicer1 protein variant, in oral cancer cells

“…Although several chemotherapeutic drugs, including cisplatin, have proven effective in the treatment of head and neck cancer [49–51], the failure of OSCCs to respond to chemotherapeutic treatments due to acquired resistance limits the overall success of these types of therapeutic strategies and in-part contributes to ~40% of oral cancer-related patient deaths [5, 52]. Therefore, to assess whether the depletion of Dicer1e could contribute towards the chemosensitization of oral cancer cells, we transfected SCC-25 cells with either siNT or siDicer1e 24 hours prior to the addition of 1.8 μM (IC 25 ) of cisplatin for 48 hours.…”